Takeda Announces Completion of Pivotal Phase 3 Trial for Dengue Vaccine Qdenga

Takeda Inc. announces completion of the 7-year pivotal Phase 3 Tides trial evaluating its dengue vaccine, Qdenga. The trial met its primary endpoint, and the vaccine candidate demonstrated 80.2% efficacy against symptomatic dengue infection in the primary analysis population. Takeda plans to submit the results to regulatory authorities for approval.